RxDoctor Payments Data

Indrajeet Mahata, MD

Clinical Cardiac Electrophysiology · Springfield, MONPI 1619225208

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (35.0%), food and beverage and grants — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 45.1% of the total. Reporting peaked in 2019 at $14,084 and has fallen 85.3% since, to $2,067 in 2025.

$24,497in general payments, 2019–2025

Across 182 payments — averaging $134.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Abbott$6K
  • Boston Scientific$4K
  • Biotronik Inc.$2K
  • Medical Device Business Services, Inc.$804
  • Kestra Medical Technology Services, Inc.$322
  • plus $461 from 6 others

What the payments were for

  • Grants$6,40026%
  • Travel & lodging$8,58235%
  • Food & beverage$8,25834%
  • Education$1,2565%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,497 in reported general payments places this provider in the 65th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$183,751
Medicare patients
1,924
Services billed
3,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban599$565,267
XareltoRivaroxaban116$140,813
EntrestoSacubitril/Valsartan145$135,223
JardianceEmpagliflozin42$39,474
Dofetilide80$12,041
Flecainide Acetate316$7,646
Amiodarone Hcl196$5,469
Metoprolol Succinate437$3,602
Diltiazem 24hr Er (Cd)Diltiazem Hcl130$3,249
Mexiletine Hcl30$2,791
Ranolazine ErRanolazine12$2,515
Bumetanide32$1,308
PaceroneAmiodarone Hcl11$1,191
Warfarin Sodium203$1,162
SotalolSotalol Hcl63$870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$34$135,223145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →